This project centers on advancing ImmunoThera BioTech’s lead immunotherapy candidate, ImmunoThera-2, through the critical phase of First-in-Human (FIH) clinical studies. MAQTOX is collaborating with ImmunoThera BioTech to design, implement, and manage FIH trials to evaluate the safety, pharmacokinetics, and efficacy of ImmunoThera-2 in human subjects. The goal is to establish its potential as a treatment for various autoimmune disorders, paving the way for further clinical development.
This project represents a crucial step toward bringing ImmunoThera-2 to market, with the potential to revolutionize the treatment of autoimmune diseases and offer novel therapeutic options for patients.